Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00259987 · ClinicalTrials.gov registry record · Phase 2
Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00259987 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants.
The verdict
NCT00259987, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This Phase II study will assess the efficacy, safety, and pharmacodynamics and pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with relapsed adenocarcinoma of the esophagus, including tumors of the GE junction and gastric cardia.
Interventions
- DRUG Lapatinib (GW572016) oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00259987
The ClinicalTrials.gov registry entry for NCT00259987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lapatinib (GW572016) oral tablets is the first listed.
NCT00259987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00259987 about?
NCT00259987 is a clinical study titled "Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus". This Phase II study will assess the efficacy, safety, and pharmacodynamics and pharmacokinetics of 1000 mg and 1500 mg lapatinib administered once daily in patients with relapsed adenocarcinoma of the esophagus, including tumors of the GE junction and gastric cardia.
What is the current status of trial NCT00259987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-11. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00259987?
The interventions under investigation include: Lapatinib (GW572016) oral tablets (DRUG).
Who is sponsoring clinical trial NCT00259987?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.